blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2941269

EP2941269 - THERAPEUTIC VACCINES FOR TREATING HERPES SIMPLEX VIRUS TYPE 2 INFECTIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.10.2021
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  06.11.2020
FormerGrant of patent is intended
Status updated on  20.06.2020
FormerExamination is in progress
Status updated on  11.05.2018
FormerRequest for examination was made
Status updated on  20.03.2017
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Mucosal Vaccine Technologies LLC
500 West Boylston St.
Worcester, MA 01606 / US
[2021/10]
Former [2020/33]For all designated states
Mucosal Vaccine Technologies LLC
57 Union Street
Worcester, MA 01608 / US
Former [2015/46]For all designated states
Biomedical Research Models, Inc.
67 Millbrook Street Suite 422
Worcester, MA 01606 / US
Inventor(s)01 / YANG, Kejian
c/o Biomedical Research Models Inc.
67 Millbrook Street
Suite 422
Worcester Massachusetts 01606 / US
02 / GUBERSKI, Dennis L.
c/o Biomedical Research Models Inc.
67 Millbrook Street
Suite 422
Worcester Massachusetts 01606 / US
 [2015/46]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2020/50]
Former [2015/46]Walton, Seán Malcolm, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date14735408.807.01.2014
[2015/46]
WO2014US10516
Priority number, dateUS201361749682P07.01.2013         Original published format: US 201361749682 P
US201361799552P15.03.2013         Original published format: US 201361799552 P
[2015/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014107731
Date:10.07.2014
Language:EN
[2014/28]
Type: A1 Application with search report 
No.:EP2941269
Date:11.11.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 10.07.2014 takes the place of the publication of the European patent application.
[2015/46]
Type: B1 Patent specification 
No.:EP2941269
Date:09.12.2020
Language:EN
[2020/50]
Search report(s)International search report - published on:US10.07.2014
(Supplementary) European search report - dispatched on:EP14.07.2016
ClassificationIPC:A61K39/245, A61K9/127
[2015/46]
CPC:
A61K39/12 (EP,US); A61P11/06 (EP); A61P25/28 (EP);
A61P31/04 (EP); A61P31/22 (EP); A61P37/08 (EP);
A61P9/10 (EP); A61K2039/543 (EP,US); A61K2039/55555 (EP,US);
A61K38/00 (EP,US); A61K39/245 (US); C07K14/005 (US);
C07K14/03 (US); C07K14/035 (US); C07K16/085 (US);
C12N2710/16634 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/46]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:THERAPEUTISCHE IMPFSTOFFE ZUR BEHANDLUNG VON HERPES-SIMPLEX-VIRUS-TYP 2-INFEKTIONEN[2015/46]
English:THERAPEUTIC VACCINES FOR TREATING HERPES SIMPLEX VIRUS TYPE 2 INFECTIONS[2015/46]
French:VACCINS THÉRAPEUTIQUES PERMETTANT DE TRAITER LES INFECTIONS PAR LE VIRUS DE L'HERPÈS SIMPLEX DE TYPE 2[2015/46]
Entry into regional phase24.07.2015National basic fee paid 
24.07.2015Search fee paid 
24.07.2015Designation fee(s) paid 
24.07.2015Examination fee paid 
Examination procedure24.07.2015Examination requested  [2015/46]
21.03.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
26.05.2017Amendment by applicant (claims and/or description)
15.05.2018Despatch of a communication from the examining division (Time limit: M06)
14.11.2018Reply to a communication from the examining division
29.06.2020Communication of intention to grant the patent
02.11.2020Fee for grant paid
02.11.2020Fee for publishing/printing paid
02.11.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.05.2018
Opposition(s)10.09.2021No opposition filed within time limit [2021/46]
Request for further processing for:The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
26.05.2017Request for further processing filed
26.05.2017Full payment received (date of receipt of payment)
Request granted
09.06.2017Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
26.05.2017Request for further processing filed
26.05.2017Full payment received (date of receipt of payment)
Request granted
09.06.2017Decision despatched
Fees paidRenewal fee
06.06.2016Renewal fee patent year 03
27.01.2017Renewal fee patent year 04
29.01.2018Renewal fee patent year 05
28.01.2019Renewal fee patent year 06
27.01.2020Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.01.201603   M06   Fee paid on   06.06.2016
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.01.2014
AL09.12.2020
AT09.12.2020
CY09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
MK09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
IE07.01.2021
LU07.01.2021
CH31.01.2021
LI31.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
DE03.08.2021
[2024/22]
Former [2023/30]HU07.01.2014
AL09.12.2020
AT09.12.2020
CY09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
IE07.01.2021
LU07.01.2021
CH31.01.2021
LI31.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
DE03.08.2021
Former [2023/27]HU07.01.2014
AL09.12.2020
AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
IE07.01.2021
LU07.01.2021
CH31.01.2021
LI31.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
DE03.08.2021
Former [2022/23]AL09.12.2020
AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
IE07.01.2021
LU07.01.2021
CH31.01.2021
LI31.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
DE03.08.2021
Former [2022/10]AL09.12.2020
AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
IE07.01.2021
LU07.01.2021
CH31.01.2021
LI31.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
DE03.08.2021
Former [2022/07]AL09.12.2020
AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
IE07.01.2021
LU07.01.2021
CH31.01.2021
LI31.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
DE03.08.2021
Former [2021/52]AL09.12.2020
AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
LU07.01.2021
CH31.01.2021
LI31.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
DE03.08.2021
Former [2021/50]AL09.12.2020
AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SI09.12.2020
SK09.12.2020
SM09.12.2020
LU07.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
DE03.08.2021
Former [2021/45]AL09.12.2020
AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SK09.12.2020
SM09.12.2020
LU07.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
Former [2021/43]AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SK09.12.2020
SM09.12.2020
LU07.01.2021
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
Former [2021/42]AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
IS09.04.2021
PT09.04.2021
Former [2021/41]AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
MC09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/39]AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
PL09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/37]AT09.12.2020
CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/36]CZ09.12.2020
EE09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/35]CZ09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
RO09.12.2020
RS09.12.2020
SE09.12.2020
SK09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/34]CZ09.12.2020
FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
RS09.12.2020
SE09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/33]FI09.12.2020
HR09.12.2020
LT09.12.2020
LV09.12.2020
RS09.12.2020
SE09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
PT09.04.2021
Former [2021/32]FI09.12.2020
HR09.12.2020
LV09.12.2020
RS09.12.2020
SE09.12.2020
SM09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
Former [2021/28]FI09.12.2020
HR09.12.2020
LV09.12.2020
RS09.12.2020
SE09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
Former [2021/24]FI09.12.2020
LV09.12.2020
RS09.12.2020
SE09.12.2020
BG09.03.2021
NO09.03.2021
GR10.03.2021
Former [2021/23]FI09.12.2020
LV09.12.2020
RS09.12.2020
SE09.12.2020
NO09.03.2021
GR10.03.2021
Former [2021/22]FI09.12.2020
RS09.12.2020
NO09.03.2021
Former [2021/20]FI09.12.2020
Documents cited:Search[Y]  - REBECCA S TIRABASSI ET AL, "A mucosal vaccination approach for herpes simplex virus type 2", VACCINE, ELSEVIER LTD, GB, vol. 29, no. 5, doi:10.1016/J.VACCINE.2010.11.076, ISSN 0264-410X, (20110129), pages 1(1090 - 1098), URL: http://www.sciencedirect.com/science/article/pii/S0264410X10017202, XP002699890 [Y] 1-15 * Discussion *

DOI:   http://dx.doi.org/10.1016/J.VACCINE.2010.11.076
 [Y]  - K. YANG ET AL, "A DNA Vaccine Prime Followed by a Liposome-Encapsulated Protein Boost Confers Enhanced Mucosal Immune Responses and Protection", THE JOURNAL OF IMMUNOLOGY, US, (20080418), vol. 180, no. 9, doi:10.4049/jimmunol.180.9.6159, ISSN 0022-1767, pages 6159 - 6167, XP055285654 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.4049/jimmunol.180.9.6159
 [Y]  - C. S. MORELLO ET AL, "Immunization with Herpes Simplex Virus 2 (HSV-2) Genes plus Inactivated HSV-2 Is Highly Protective against Acute and Recurrent HSV-2 Disease", JOURNAL OF VIROLOGY, (20110126), vol. 85, no. 7, doi:10.1128/JVI.02521-10, ISSN 0022-538X, pages 3461 - 3472, XP055142132 [Y] 1-15 * page 3465, column l, paragraph last *

DOI:   http://dx.doi.org/10.1128/JVI.02521-10
International search[Y]US2012027841  (YANG KEJIAN [US], et al);
 [Y]US2012308598  (MUELLER ANN-KRISTIN [DE], et al);
 [A]US2012328658  (VILALTA ADRIAN [US], et al)
by applicantUS4426330
 US4534899
 WO8804924
 US4837028
 WO9001496
 EP0366412
 WO9004384
 WO9006951
 WO9105545
 US5013556
 US5213804
 WO9310152
 US5225212
 US5290563
 EP0445131
 WO9420073
 US5356633
 EP0496813
 WO9610391
 US5540935
 US5543152
 US5556948
 WO9713499
 US5843464
 WO9903884
 WO9917741
 WO9928475
 WO9927944
 WO9951748
 US2012027841
    - COHEN, Science, (20100000), vol. 330, page 304
    - BERNSTEIN; STANBERRY, Vaccine, (19990000), vol. 17, no. 13-14, pages 1681 - 1689
    - KRAUSE; STRAUS, Infect Dis Clin North Am., (19990000), vol. 13, no. 1, pages 61 - 81
    - MCKENZIE; STRAUS, Rev Med Virol., (19960000), vol. 6, pages 85 - 96
    - BELARDELLI et al., Cancer Res., (20040000), vol. 64, pages 6827 - 6830
    - Biochem Biophys Acta, (19890000), vol. 67, page 1007
    - RUBINS et al., Microbial Pathogenesis, vol. 25, pages 337 - 342
    - MANIATIS et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Press, (19890000), vol. 1-3
    - HAYNES et al., J. Biotechnology, (19960000), vol. 44, pages 37 - 42
    - IM; HANKE, Expert, Rev. Vaccines, (20040000), vol. 3, pages S89 - S97
    - BASAK et al., Viral Immunol., (20040000), vol. 17, pages 182 - 196
    - DORIA-ROSE; HAIGWOOD, Methods, (20030000), vol. 31, pages 207 - 216
    - LEIFERT et al., Immunol. Rev., (20040000), vol. 199, pages 40 - 53
    - ALLEN et al., FEBS Letters, (19870000), vol. 223, page 42
    - WU et al., Cancer Research, (19930000), vol. 53, page 3765
    - PAPAHADJOPOULOS et al., Ann. N.Y. Acad. Sci., (19870000), vol. 507, page 64
    - GABIZON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, page 6949
    - SUNAMOTO et al., Bull. Chem. Soc. Jpn., (19800000), vol. 53, page 2778
    - ILIUM et al., FEBS Letters, (19840000), vol. 167, page 79
    - KLIBANOV et al., FEBS Letts., (19900000), vol. 268, page 235
    - BLUME et al., Biochimica et Biophysica Acta, (19900000), vol. 1029, page 91
    - AKHTAR et al., Nucl. Acids Res., (19910000), vol. 19, page 5551
    - YACHI et al., Biopharm. Drug Dispos., (19960000), vol. 17, page 699
    - FARMER et al., Meth. Enz., (19870000), vol. 149, page 184
    - BRODT et al., Cancer Immunol. Immunother., (19890000), vol. 28, page 54
    - PEREZ-SOLER et al., J. Nuclear Med., (19850000), vol. 26, page 743
    - WASAN et al., Antimicrobial Agents and Chemotherapy, (19930000), vol. 37, page 246
    - LI et al., Oncology Res., (19950000), vol. 7, page 611
    - KASTURI et al., Nature, (20110000), vol. 470, pages 543 - 560
    - ALVING, Vaccine, (20020000), vol. 20, no. 3, pages S56 - S64
    - HUNTER, Vaccine, (20020000), vol. 20, no. 3, pages 7 - 12
    - PETROVSKY; AGUILAR, Immunol. Cell Biol., (20040000), vol. 82, pages 488 - 496
    - STANBERRY et al., Intervirology, (19850000), vol. 24, no. 4, pages 226 - 231
    - STANBERRY et al., J Infect Dis, (19820000), vol. 146, no. 3, pages 397 - 404
    - WHITLEY; ROIZMAN, Lancet, (20010000), vol. 357, no. 9267, pages 1513 - 1518
    - HANDSFIELD HH; STONE KM; WASSERHEIT JN, "Prevention agenda for genital herpes", Sex Transm Dis, (19990000), vol. 26, no. 4, pages 228 - 31
    - LAFFERTY WE; COOMBS RW; BENEDETTI J; CRITCHLOW C; COREY L, "Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type", N Engl J Med, (19870000), vol. 316, no. 23, pages 1444 - 9
    - MERTZ GJ; BENEDETTI J; ASHLEY R; SELKE SA; COREY L, "Risk factors for the sexual transmission of genital herpes", Ann Intern Med, (19920000), vol. 116, no. 3, pages 197 - 202
    - WALD A; COREY L; CONE R; HOBSON A; DAVIS G; ZEH J., "Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment", J Clin Invest, (19970000), vol. 99, no. 5, pages 1092 - 7
    - "Herpes simplex viruses", STRAUS S; COREY L., Mandell, Douglas, and Bennett's principles and practice of infectious diseases, Churchill Livingstone, (20000000), pages 1556 - 80
    - KIMBERLIN DW., "Antiviral therapy for cytomegalovirus infections in pediatric patients", Semin Pediatr Infect Dis, (20020000), vol. 13, no. 1, pages 22 - 30
    - STAMM WE; HANDSFIELD HH; ROMPALO AM; ASHLEY RL; ROBERTS PL; COREY L, "The association between genital ulcer disease and acquisition of HIV infection in homosexual men", JAMA, (19880000), vol. 260, no. 10, pages 1429 - 33
    - STANBERRY LR; SPRUANCE SL; CUNNINGHAM AL; BERNSTEIN DI; MINDEL A; SACKS S et al., "Glycoprotein-d-adjuvant vaccine to prevent genital herpes", N Engl J Med, (20020000), vol. 347, no. 21, pages 1652 - 61
    - WHITLEY RJ; KIMBERLIN DW; ROIZMAN B., "Herpes simplex viruses", Clin Infect Dis, (19980000), vol. 26, no. 3, pages 541 - 53
    - ASHLEY RL; DALESSIO J; BURCHETT S; BROWN Z; BERRY S; MOHAN K et al., "Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth", J Clin Invest, (19920000), vol. 90, no. 2, pages 511 - 4
    - DUDLEY KL; BOURNE N; MILLIGAN GN, "Immune protection against HSV-2 in B-cell-deficient mice", Virology, (20000000), vol. 270, no. 2, doi:doi:10.1006/viro.2000.0298, pages 454 - 63, XP004436315

DOI:   http://dx.doi.org/10.1006/viro.2000.0298
    - "The immunobiology of herpes simplex virus", MESTER JC; MILLIGAN GN; BERNSTEIN DI, Genital and neonatal herpes, John Wiley and Sons, Ltd., (19960000), pages 49 - 91
    - MILLIGAN GN; BERNSTEIN DI, "Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2", Virology, (19950000), vol. 212, no. 2, doi:doi:10.1006/viro.1995.1506, pages 481 - 9, XP026703709

DOI:   http://dx.doi.org/10.1006/viro.1995.1506
    - SPECK P; SIMMONS A, "Precipitous clearance of herpes simplex virus antigens from the peripheral nervous systems of experimentally infected C57BL/10 mice", J Gen Virol, (19980000), vol. 79, pages 561 - 4
    - KOELLE DM; POSAVAD CM; BARNUM GR; JOHNSON ML; FRANK JM; COREY L, "Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes", J Clin Invest, (19980000), vol. 101, no. 7, pages 1500 - 8
    - POSAVAD CM; KOELLE DM; SHAUGHNESSY MF; COREY L, "Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses", Proc Natl Acad Sci USA, (19970000), vol. 94, no. 19, pages 10289 - 94
    - POSAVAD CM; KOELLE DM; COREY L, "Tipping the scales of herpes simplex virus reactivation: the important responses are local", Nat Med, (19980000), vol. 4, no. 4, pages 381 - 2
    - "Mucosal immunity in the female and male reproductive tracts", PARR MB; PARR EL, Handbook of mucosal immunology, Academic Press, (19940000), pages 677 - 89
    - PARR MB; PARR EL, "Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes", J Virol, (19980000), vol. 72, no. 4, pages 2677 - 85
    - MILLIGAN GN; BERNSTEIN DI; BOURNE N, "T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2", J Immunol, (19980000), vol. 160, no. 12, pages 6093 - 100
    - KUKLIN NA; DAHESHIA M; CHUN S; ROUSE BT, "Role of mucosal immunity in herpes simplex virus infection", J Immunol, (19980000), vol. 160, no. 12, pages 5998 - 6003, XP002164286
    - GALLICHAN WS; ROSENTHAL KL, "Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization", J Infect Dis, (19980000), vol. 177, no. 5, pages 1155 - 61
    - NEUTRA MR; KOZLOWSKI PA, "Mucosal vaccines: the promise and the challenge", Nat Rev Immunol, (20060000), vol. 6, no. 2, doi:doi:10.1038/nri1777, pages 148 - 58, XP008068374

DOI:   http://dx.doi.org/10.1038/nri1777
    - SEDER RA; HILL AV., "Vaccines against intracellular infections requiring cellular immunity", Nature, (20000000), vol. 406, no. 6797, doi:doi:10.1038/35021239, pages 793 - 8, XP001008813

DOI:   http://dx.doi.org/10.1038/35021239
    - ROBINSON HL; MONTEFIORI DC; JOHNSON RP; MANSON KH; KALISH ML; LIFSON JD et al., "Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations", Nat Med, (19990000), vol. 5, no. 5, doi:doi:10.1038/8406, pages 526 - 34, XP001135061

DOI:   http://dx.doi.org/10.1038/8406
    - YANG K; WHALEN BJ; TIRABASSI RS; SELIN LK; LEVCHENKO TS; TORCHILIN VP et al., "A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection", J Immunol, (20080000), vol. 180, no. 9, doi:doi:10.4049/jimmunol.180.9.6159, pages 6159 - 67, XP055285654

DOI:   http://dx.doi.org/10.4049/jimmunol.180.9.6159
    - O'HAGAN DT., "Recent developments in vaccine delivery systems", Curr Drug Targets Infect Disord, (20010000), vol. 1, no. 3, pages 273 - 86
    - ALVING CR; KOULCHIN V; GLENN GM; RAO M., "Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides", Immunol Rev, (19950000), vol. 145, pages 5 - 31
    - BOURNE N; MILLIGAN GN; SCHLEISS MR; BERNSTEIN DI; STANBERRY LR, "DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2", Vaccine, (19960000), vol. 14, no. 13, doi:doi:10.1016/S0264-410X(96)00027-8, pages 1230 - 4, XP004069591

DOI:   http://dx.doi.org/10.1016/S0264-410X(96)00027-8
    - BERNSTEIN DI; TEPE ER; MESTER JC; ARNOLD RL; STANBERRY LR; HIGGINS T, "Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection", Vaccine, (19990000), vol. 17, no. 15-16, pages 1964 - 9
    - CATTAMANCHI A; POSAVAD CM; WALD A; BAINE Y; MOSES J; HIGGINS TJ et al., "Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2 seronegative adults by a needle-free injection system", Clin Vaccine Immunol, (20080000), vol. 15, no. 11, doi:doi:10.1128/CVI.00167-08, pages 1638 - 43, XP055194059

DOI:   http://dx.doi.org/10.1128/CVI.00167-08
    - POSAVAD CM; REMINGTON M; MUELLER DE; ZHAO L; MAGARET AS; WALD A et al., "Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons", J Immunol, (20100000), vol. 184, no. 6, doi:doi:10.4049/jimmunol.0900722, pages 3250 - 9, XP055041915

DOI:   http://dx.doi.org/10.4049/jimmunol.0900722
    - PERTMER TM; ROBERTS TR; HAYNES JR, "Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery", J Virol, (19960000), vol. 70, no. 9, pages 6119 - 25
    - FELTQUATE DM; HEANEY S; WEBSTER RG; ROBINSON HL, "Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization", J Immunol, (19970000), vol. 158, no. 5, pages 2278 - 84, XP002098283
    - PARR MB; PARR EL, "The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice", Virology, (19990000), vol. 258, no. 2, doi:doi:10.1006/viro.1999.9739, pages 282 - 294, XP004439897

DOI:   http://dx.doi.org/10.1006/viro.1999.9739
    - MILLIGAN GN; BERNSTEIN DI, "Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract", Virology, (19970000), vol. 229, no. l, doi:doi:10.1006/viro.1997.8441, pages 259 - 268, XP004460180

DOI:   http://dx.doi.org/10.1006/viro.1997.8441
    - BARAL RN; SAHA A; CHATTCRJCC SK; FOON KA; KRIEG AM; WEINER GJ et al., "Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen", Cancer Immunol Immunother, (20030000), vol. 52, no. 5, pages 317 - 327
    - SANDLER AD; CHIHARA H; KOBAYASHI G; ZHU X; MILLER MA; SCOTT DL et al., "CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma", Cancer Res, (20030000), vol. 63, no. 2, pages 394 - 399
    - KUTZLER MA; WEINER DB, "DNA vaccines: ready for prime time?", Nat Rev Genet, (20080000), vol. 9, no. 10, doi:doi:10.1038/nrg2432, pages 776 - 788, XP002621067

DOI:   http://dx.doi.org/10.1038/nrg2432
    - LU S., "Immunogenicity of DNA vaccines in humans: it takes two to tango", Hum Vaccin, (20080000), vol. 4, no. 6, pages 449 - 452
    - DOMINGO C; GADEA I; PARDEIRO M; CASTILLA C; FERNANDEZ S; FERNANDEZ-CLUA MA et al., "Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D", Vaccine, (20030000), vol. 21, no. 25-26, doi:doi:10.1016/S0264-410X(03)00423-7, pages 3565 - 3574, XP004446125

DOI:   http://dx.doi.org/10.1016/S0264-410X(03)00423-7
    - BRIDGES PA; TAYLOR KM, "The effects of freeze-drying on the stability of liposomes to jet nebulization", J Pharm Pharmacol, (20010000), vol. 53, no. 3, doi:doi:10.1211/0022357011775451, pages 393 - 398, XP009066334

DOI:   http://dx.doi.org/10.1211/0022357011775451
    - BRIDGES PA; TAYLOR KM, "An investigation of some of the factors influencing the jet nebulisation of liposomes", Int J Pharm, (20000000), vol. 204, no. 1-2, pages 69 - 79, XP027379990
    - ALVING CR, "Design and selection of vaccine adjuvants: animal models and human trials", Vaccine, (20020000), vol. 20, no. 3, doi:doi:10.1016/S0264-410X(02)00174-3, pages S56 - S64, XP004361376

DOI:   http://dx.doi.org/10.1016/S0264-410X(02)00174-3
    - MOYNIHAN JS; JONES DH; FARRAR GH; HOWARD CR, "A novel microencapsulated peptide vaccine against hepatitis B.", Vaccine, (20010000), vol. 19, no. 23-24, doi:doi:10.1016/S0264-410X(00)00540-5, pages 3292 - 3300, XP004234204

DOI:   http://dx.doi.org/10.1016/S0264-410X(00)00540-5
    - NATUK RJ; COOPER D; GUO M; CALDERON P; WRIGHT KJ; NASAR F et al., "Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Thl immune responses and are protective in mouse and guinea pig models of vaginal challenge", J Virol, (20060000), vol. 80, no. 9, pages 4447 - 447
 GB19910024390
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.